The global Huntington’s disease treatment market size is anticipated to register a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing improved symptomatic therapies, growing targeted population, and promising disease-modifying therapies in the developmental pipeline.
Huntington’s disease (HD) is a hereditary neurodegenerative disorder of the central nervous system which is categorized by combination of motor, cognitive, and psychiatric symptoms. Results of this disease is progressive degeneration of the brain cells. In 1872, a physician named George Huntington, described the disorder as a hereditary chorea. Hence, earlier it was called as Huntington’s chorea or HC.
The symptoms of Huntington’s disease generally developed in adulthood between the age of 30 years and 40 years. If the symptoms developed before 20 years then it is called as juvenile Huntington’s disease. In the U.S., every year around 30,000 cases of HD are found and approximately, 15% of all cases are affected by Juvenile HD. Both men and women are equally affected. The disease causes several different symptoms in patient which leads to trouble in motor control (movement), cognition (thinking), and behavior.
Patients having HD also has muscle problems such as posture, muscle contracture (dystonia) or rigidity, balance, and impaired gait. Cognition disorder and substantial behavior related to HD is depression which results because of brain injury and loss of brain function. Presently, Xenazine and Austedo are only two symptom-alleviating therapies which are approved for HD. The market inclination of drug-development approach is shifting from conventional symptomatic therapies to disease-modifying therapies. This is driven by the pathogenesis of this disorder.
Market Trends, Drivers, Restraints, and Opportunities
- Growing prevalence of Huntington’s disease and rising research and development programs in various institutes and universities are projected to drive the market expansion in the coming years.
- Increasing improved symptomatic therapies and rising pipelines of novel therapies are anticipated to fuel the market growth.
- Unmet medical needs and rising awareness about Huntington’s disease are expected to propel the expansion of the market during the forecast period.
- Rising investments in research and development sector by various pharmaceutical companies is estimated to spur the market growth in the coming years.
- Presence of alternative therapies such as speech therapy, psychotherapy, and physiotherapy are projected to boost the market growth.
- Stringent regulations and limited approved drug are major factor responsible for hampering the growth of the market in the coming years.
Scope of the Report
The report on the global Huntington’s disease treatment market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
| Attributes | Details |
| Report Title | Huntington’s Disease Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
| Base Year | 2020 |
| Historic Data | 2018–2019 |
| Forecast Period | 2021–2028 |
| Segmentation | Treatments (Symptomatic Therapy and Disease-modifying Therapy) |
| Regional Scope | Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
| Report Coverage | Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
| Key Players Covered in the Report | Valeant Pharmaceuticals, Teva Pharmaceuticals, Wave Life Sciences, Ionis Pharmaceuticals/ Roche, Raptor Pharmaceuticals, Prana Biotechnology, Alnylam Pharmaceuticals, Inc., AmpliPhi Biosciences Corp, Pfizer, Lundbeck, Cortex Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, GlaxoSmithKline, Auspex Pharmaceuticals, Ceregene Inc., SOM Biotech, Siena Biotech, Palobiofarma, and Ipsen |
Market Segment Insights
Disease-modifying therapy segment is expected to grow at a significant pace
Based on treatments, the Huntington’s disease treatment market is bifurcated into symptomatic therapy and disease-modifying therapy. The symptomatic treatment segment is expected to hold a key share of the market during the forecast period. In this treatment drugs are used such as tetrabenazine, antidepressants, antipsychotic or mood-stabilizing. Moreover, speech therapy, home remedies, psychotherapy, occupational therapy or lifestyle, and physical therapy are important for the improvement in the life of the patient.
However, the disease-modifying therapy segment is anticipated to expand at a rapid pace during the forecast period owing to launch of several novel products and rising R&D sector. Presently, research in HD targets on use of novel treatments including immuno-modulating therapies and gene therapy such as zinc-finger DNA binding protein (ZFP), antisense oligonucleotides, mRNA splicing, and micro RNAs (miRNA).
North America is expected to dominate the market
On the basis of regions, the Huntington’s disease treatment market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to increasing adoption of novel therapeutics, presence of major market players, and multiple product launches. Furthermore, rising activities in R&D sector, increasing investment by pharmaceutical companies in the region are expected to fuel the market growth in the coming years. Also, more effective and improved drugs, innovative and advanced technology, and increasing number of vendors are projected to drive the market expansion.
On the other hand, the market of Europe is expected to exhibit a rapid growth rate in the coming years owing to rising awareness of disease among people and increasing infrastructure for scientific research.
Segments
Segments Covered in the Report
The global Huntington’s disease treatment market has been segmented on the basis of
Treatments
- Symptomatic Therapy and
- Disease-modifying Therapy
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Valeant Pharmaceuticals
- Teva Pharmaceuticals
- Wave Life Sciences
- Ionis Pharmaceuticals/ Roche
- Raptor Pharmaceuticals
- Prana Biotechnology
- Alnylam Pharmaceuticals, Inc.
- AmpliPhi Biosciences Corp
- Pfizer
- Lundbeck
- Cortex Pharmaceuticals Inc.
- Vertex Pharmaceuticals Incorporated
- GlaxoSmithKline
- Auspex Pharmaceuticals
- Ceregene Inc.
- SOM Biotech
- Siena Biotech
- Palobiofarma
- Ipsen
Competitive Landscape
Key players competing in the Huntington’s disease treatment market are Valeant Pharmaceuticals, Teva Pharmaceuticals, Wave Life Sciences, Ionis Pharmaceuticals/ Roche, Raptor Pharmaceuticals, Prana Biotechnology, Alnylam Pharmaceuticals, Inc., AmpliPhi Biosciences Corp, Pfizer, Lundbeck, Cortex Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, GlaxoSmithKline, Auspex Pharmaceuticals, Ceregene Inc., SOM Biotech, Siena Biotech, Palobiofarma, and Ipsen.
Major market players are adopting several business strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares.
Request For Customization
Enquiry Before Buying
Speak With Analyst
